GlassScriptPhysician profile
Mohammad Jahangiri
NPI 1174142202
$2,958.15
in general payments reported to CMS, 2019-2025
24 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $239 · 2023: $991 · 2024: $882 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $529.75 | 2023-2025 | Briviact, Fintepla, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $509.52 | 2022-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $350.40 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.45 | 2023-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $197.27 | 2022-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $115.09 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $111.53 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $107.98 | 2023-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $98.04 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $97.45 | 2023-2025 | Fasenra, Andexxa |
| Abbvie INC. | $92.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $91.52 | 2025 | |
| Upsher-Smith Laboratories LLC | $68.00 | 2025 | |
| Biogen, INC. | $67.44 | 2022-2024 | Tysabri, Vumerity, Skyclarys |
| Eisai INC. | $59.97 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $59.41 | 2024-2025 | Ingrezza |
| Merz Pharmaceuticals, LLC | $27.93 | 2024 | Xeomin |
| Neurelis, INC. | $24.40 | 2023 | Valtoco |
| Azurity Pharmaceuticals, INC. | $24.38 | 2024 | Zonisade |
| Mallinckrodt Hospital Products INC. | $20.03 | 2025 | Acthar |
| Immedica Pharma US, INC. | $18.68 | 2023 | |
| Janssen Biotech, INC. | $18.35 | 2025 | Tremfya |
| Catalyst Pharmaceuticals, INC. | $16.60 | 2023 | Fycompa |
| Ani Pharmaceuticals, INC. | $14.90 | 2023 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Jahangiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.